Access cutting-edge primary immunodeficiency diseases treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.
Access primary immunodeficiency diseases specialists in Dallas at no cost
This study follows strict safety protocols and ethical guidelines
All study-related primary immunodeficiency diseases treatment provided free
The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035). The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the d
Sponsor: Takeda
Check if you qualify for this primary immunodeficiency diseases clinical trial in Dallas, TX
If you're searching for primary immunodeficiency diseases treatment options in Dallas, TX, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary immunodeficiency diseases specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.